A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma

201326 citationsJournal Article

Authors

Good health and well-being

Published in: Investigational New Drugs

Volume 31, Issue 6, pp. 1530-1538

Field-Weighted Citation Impact: 1.13